Introduction

Small-volume radiotherapy, which uses a small planning target volume (PTV) margin either with a single dose or hypofractionation, is widely used for metastatic brain tumours. Stereotactic radiosurgery or hypofractionated radiotherapy shows an 80–90% local control rate, even for so-called radio resistant tumours such as renal cell carcinoma and melanoma\textsuperscript{1,2}. Because of its success, small-volume radiotherapy has been applied to extracranial lesions, such as lung and liver tumours, using various techniques\textsuperscript{3-5}. Although for patients with Stage I non-small-cell lung cancer (NSCLC), surgery is the primary treatment of choice, radiotherapy is often indicated if the patients have a medically inoperable condition such as poor pulmonary or cardiac function. The results of conventional radiotherapy for Stage I lung cancer, however, are not satisfactory. Five-year actuarial survival of convention radiotherapy ranged from 6% to 27\%\textsuperscript{6-9}, which was unsatisfactory compared with surgery, which has a 5-year survival rate of 60% to 80%, even considering that poor-risk patients receive the radiotherapy series\textsuperscript{10}. Because some studies reported that patients with lung cancers who received high-dose radiation\textsuperscript{10-12} and those who received a high dose in a short period\textsuperscript{10} survived for a longer period, dose escalation in a short treatment time may improve the survival rate for NSCLC patients\textsuperscript{13-15}.

Metastatic lung cancer is common in cancer patients, and its prognosis is usually poor. But some patients with slow-growing tumours survive for longer periods\textsuperscript{16}. These patients are sometimes managed with surgical resection of the metastatic lesions to reduce the possibility of symptomatic complications and to prolong their symptom-free status.

In 1995, Blomgren et al. introduced a new stereotactic treatment technique for extracranial radiotherapy that was analogous to radiosurgery in the brain\textsuperscript{38}. The treatment of liver and lung tumours seemed very promising, leading to superior local control, with only 1 recurrence in 40 treated tumours. Based on these data, in 1997 we started a Phase I/II study for focused stereotactic radiosurgery of localized liver and lung tumors, though, in contrast to Blomgren et al.\textsuperscript{38}, strictly pursuing a single-dose concept\textsuperscript{39}. It was shown that precise patient positioning and tumour stabilization could be achieved, allowing for high single-dose treatment.

Materials and methods

Between November 2001 and December 2003, 60 patients affected by a primary or recurrent lung cancer or by lung metastases were treated with hypofractionated stereotactic arc radiotherapy. Radiotherapy was delivered with a 6-15 MeV linear Accelerator using an arc technique with a micro-multi-leaf device. Totally we treated 71 lung tumours, with a total number of 278 fractions of stereotactic body radiosurgery. Of these patients 15/60 had a lung metastasis by a distal cancer (5 from breast, 5 rectum, 3 larynx, 1 kidney, 1 melanoma), 17/60 were lung metastases from a NSCLC, 18 were primitive lung cancers (NSCLC) al 10 were local recurrences of NSCLC.

Of these patients 17/60 received also a treatment with external beam radiotherapy (EBRT) previously, and 32/60 were also treated with chemotherapy.

Some of the patients had multiple lesions, but the majority (51/60) had a single lesion. There were 4 patients with 3 lung metastases each and 5 patients with 2. Some (17/60) had also non pulmonary metastasis (3 brain, 5 liver, 3 surrenal gland, 10 bone). Four patients had multiple lesions.

The median diameter of the treated lesions was of 2.5 cm (range 0.7-5 cm).

The prescribed dose per fraction ranged between 4 Gy and 10 Gy (10 Gy in 10 treatments, 9 Gy in 52 treatments, and a dose lower than 9 Gy in 9 treatments).

The prescribed total dose ranged between 30 Gy and 40 Gy (30 Gy in 2 treatments, 32 Gy in 3, 36 Gy in 56, 40 Gy in 10).

The treatments lasted between 11 and 26 days each.

The number of fractions ranged between 4 and 8 for each treatment (4 fractions in 68, 6 fractions in 2, 8 fractions in 1). The number of arcs for each therapy ranged between 3 and 7. In the majority it was delivered with 4 or 5 arcs. More than 90% of the PTV was delivered the prescribed dose in the majority of cases (average; 96%, range; 74-100%). Two pre-
Results

The median follow up is of 9 months (range 1-24 months).

Patients were seen and examined by one or two of the investigating physicians a minimum of once per month in the first 6 months of the follow-up period and every 3 months thereafter. This evaluation included a physical examination, laboratory evaluation, and chest CT scan. A respiratory function test was obtained in patients who agreed to do it regularly during the follow-up.

We obtained an improvement of symptoms with a regression of the respiratory distress in 16 patients (25%) and a reduction of the volume valuable at the CT scan in 32 patients (50%).

In 20 patients (33%) we obtained a RP, in 25 (41%) a stable disease (SD), in 15 (25%) it was diagnosed a local progression of the tumor.

Totally 15 patients died for the consequences of the extra-pulmonary disease (7 of these had also a local progression).

In 27/60 patients it was described an asymptomatic lung fibrosis medically 4 months after treatment. Only 5/60 patients had an increased dyspnoea.

Discussion

In some experiences with hypofractionated stereotactic radiosurgery the 3-year local control rate was 80.4% ± 7.1% (a standard error) with a median follow-up period of 17 months for survivors. The 3-year local control rate was 69.6 ± 10.6% for patients who received 48 Gy and 100% for patients who received 60 Gy.

But in this series because of the Grade 5 toxicity, they halted this Phase I/II study and planned to rearrange the protocol setting. We didn’t recorded such side effects.

Organ movement is an important issue as a source of uncertainty in our study. Systematic or preparatory error resulting from organ motion can significantly increase or decrease the dose distribution for the critical organs in general. Intrafractional organ motion can affect dose distribution considerably for lung tissues. Breath-holding, gating, and respiratory synchrony have been used to reduce the uncertainty resulting from respiratory motion. Technical developments may effectively reduce the safety margin for internal motion, but their clinical importance should be compared carefully with the technique introduced in the current study because our method does not require investment in new equipment.

Stereotactic treatment of lung tumors is described by some authors. Nakagawa et al. treated 22 thoracic tumors with single doses between 15 and 24 Gy. During a median follow-up of 8 months, only 1 local recurrence was seen. A concept of hypofractionated treatment in up to 3 treatment sessions was pursued by Blomgren et al. in most of the 17 irradiated lung tumors. Sixteen of these presented at least stable disease in the mean follow-up period of 8.2 months. A similar approach was taken by Wulf et al., achieving 76% actuarial local control after 2 years in 27 treated lung tumors. Even smaller fraction-doses (total dose: 50-60 Gy in 5-10 fractions) were used by Uematsu et al. for the treatment of Stage I NSCLC. In a relatively large group of 50 patients with a long median follow-up of 36 months, local tumor control was achieved in 94% of the patients. Yet, it has to be mentioned that 18 patients had received conventional radiotherapy earlier.

According to these encouraging results, our own data seem to be comparable given the small patient numbers in most of the studies presented, while offering the advantage of reasonable time-effort with the single-fraction treatment.

Optimal indication of this technique is controversial. Although its local control rate for metastatic thoracic tumors is favorable, most of them, small lung metastases in particular, are symptom free. This point is contrary to the symptomatic brain metastasis and may limit clinical value of the treatment. However, solitary metastases that appear during long follow-up may be suitable for it. Furthermore, several previous papers reported encouraging results with limited field radiation therapy for early-stage (T1-2N0) non-small-cell peripheral lung cancer.

References


